Related references
Note: Only part of the references are listed.Upregulation of CD38 expression on multiple myeloma cells by novel HDAC6 inhibitors is a class effect and augments the efficacy of daratumumab
Estefania Garcia-Guerrero et al.
LEUKEMIA (2021)
Discovery of selective HDAC/BRD4 dual inhibitors as epigenetic probes
Jingjing Chen et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2021)
Mercaptoacetamide: A promising zinc-binding group for the discovery of selective histone deacetylase 6 inhibitors
Mauricio T. Tavares et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2021)
HDAC6 as privileged target in drug discovery: A perspective
Sravani Pulya et al.
PHARMACOLOGICAL RESEARCH (2021)
Novel quinolone-based potent and selective HDAC6 inhibitors: Synthesis, molecular modeling studies and biological investigation
Nicola Relitti et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2021)
Old but Gold: Tracking the New Guise of Histone Deacetylase 6 (HDAC6) Enzyme as a Biomarker and Therapeutic Target in Rare Diseases
Margherita Brindisi et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Histone deacetylase 6 promotes growth of glioblastoma through the MKK7/JNK/c-Jun signaling pathway
Ziyan Huang et al.
JOURNAL OF NEUROCHEMISTRY (2020)
Heat Shock Protein 90 Inhibitors: An Update on Achievements, Challenges, and Future Directions
Li Li et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Synthesis and biological evaluation of 2-quinolineacrylamides
Shih-Wei Wang et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2020)
Structural determinants of affinity and selectivity in the binding of inhibitors to histone deacetylase 6
Jeremy D. Osko et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2020)
Novel 2, 5-diketopiperazine derivatives as potent selective histone deacetylase 6 inhibitors: Rational design, synthesis and antiproliferative activity
Xin Chen et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2020)
Thiazole-containing compounds as therapeutic targets for cancer therapy
Prabodh Chander Sharma et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2020)
Isoindoline scaffold-based dual inhibitors of HDAC6 and HSP90 suppressing the growth of lung cancer in vitro and in vivo
Ritu Ojha et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2020)
HDAC6 inhibition promotes α-tubulin acetylation and ameliorates CMT2A peripheral neuropathy in mice
Cristina Picci et al.
EXPERIMENTAL NEUROLOGY (2020)
A patent review of histone deacetylase 6 inhibitors in neurodegenerative diseases (2014-2019)
Sida Shen et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2020)
Exploring Structural Determinants of Inhibitor Affinity and Selectivity in Complexes with Histone Deacetylase 6
Jeremy D. Osko et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Preclinical validation of Alpha-Enolase (ENO1) as a novel immunometabolic target in multiple myeloma
Arghya Ray et al.
ONCOGENE (2020)
PROTACs: A novel strategy for cancer therapy
Jing Liu et al.
SEMINARS IN CANCER BIOLOGY (2020)
Structural and in Vivo Characterization of Tubastatin A, a Widely Used Histone Deacetylase 6 Inhibitor
Sida Shen et al.
ACS MEDICINAL CHEMISTRY LETTERS (2020)
Citarinostat and Momelotinib co-target HDAC6 and JAK2/STAT3 in lymphoid malignant cell lines: a potential new therapeutic combination
Maria Cosenza et al.
APOPTOSIS (2020)
HDAC6 inhibitors: Translating genetic and molecular insights into a therapy for axonal CMT
Elisabeth Rossaert et al.
BRAIN RESEARCH (2020)
Synthesis and biological evaluation of acridine-based histone deacetylase inhibitors as multitarget agents against Alzheimer's disease
Hui-Ju Tseng et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2020)
Indocyanine Green-Nexturastat A-PLGA Nanoparticles Combine Photothermal and Epigenetic Therapy for Melanoma
Debbie K. Ledezma et al.
NANOMATERIALS (2020)
The role of HSP90 molecular chaperones in hepatocellular carcinoma
Masoud Nouri-Vaskeh et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2020)
Design, Synthesis, and Biological Evaluation of Quinazolin-4-one-Based Hydroxamic Acids as Dual PI3K/HDAC Inhibitors
Ashish Thakur et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Discovery of N-Ethyl-4-[2-(4-fluoro-2,6-dimethyl-phenoxy)-5-(1-hydroxy-1-methyl-ethyl)phenyl]-6-methyl-7-oxo-1H-pyrrolo[2,3-c]pyridine-2-carboxamide (ABBV-744), a BET Bromodomain Inhibitor with Selectivity for the Second Bromodomain
George S. Sheppard et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Development of Selective Histone Deacetylase 6 (HDAC6) Degraders Recruiting Von Hippel-Lindau (VHL) E3 Ubiquitin Ligase
Ka Yang et al.
ACS MEDICINAL CHEMISTRY LETTERS (2020)
Pharmacological Inhibition of HDAC6 Attenuates NLRP3 Inflammatory Response and Protects Dopaminergic Neurons in Experimental Models of Parkinson's Disease
Shaoqi Yan et al.
FRONTIERS IN AGING NEUROSCIENCE (2020)
Analysis of Dual Class I Histone Deacetylase and Lysine Demethylase Inhibitor Domatinostat (4SC-202) on Growth and Cellular and Genomic Landscape of Atypical Teratoid/Rhabdoid
Mariah M. Hoffman et al.
CANCERS (2020)
Design of Dual Inhibitors of Histone Deacetylase 6 and Heat Shock Protein 90
Luca Pinzi et al.
ACS OMEGA (2020)
Screening of an Epigenetic Drug Library Identifies 4-((hydroxyamino)carbonyl)-N-(2-hydroxyethyl)-N-Phenyl-Benzeneacetamide that Reduces Melanin Synthesis by Inhibiting Tyrosinase Activity Independently of Epigenetic Mechanisms
Hyerim Song et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Inhibition of HDAC6 Attenuates Diabetes-Induced Retinal Redox Imbalance and Microangiopathy
Hossameldin Abouhish et al.
ANTIOXIDANTS (2020)
Thirty Years of HDAC Inhibitors: 2020 Insight and Hindsight
Terence C. S. Ho et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
A452, HDAC6-selective inhibitor synergistically enhances the anticancer activity of immunomodulatory drugs in IMiDs-resistant multiple myeloma
Go Woon Kim et al.
LEUKEMIA RESEARCH (2020)
Overexpression of HDAC6, but not HDAC3 and HDAC4 in the penumbra after photothrombotic stroke in the rat cerebral cortex and the neuroprotective effects of α-phenyl tropolone, HPOB, and sodium valproate
S. Demyanenko et al.
BRAIN RESEARCH BULLETIN (2020)
Characterization of a new small-molecule inhibitor of HDAC6 in glioblastoma
Jaione Auzmendi-Iriarte et al.
CELL DEATH & DISEASE (2020)
Recent update on discovery and development of Hsp90 inhibitors as senolytic agents
Sayan Dutta Gupta et al.
INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES (2020)
Multicomponent Synthesis, Binding Mode, and Structure-Activity Relationship of Selective Histone Deacetylase 6 (HDAC6) Inhibitors with Bifurcated Capping Groups
Nina Ressing et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Rational Design of Suprastat: A Novel Selective Histone Deacetylase 6 Inhibitor with the Ability to Potentiate Immunotherapy in Melanoma Models
Satish Noonepalle et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Spiroindoline-Capped Selective HDAC6 Inhibitors: Design, Synthesis, Structural Analysis, and Biological Evaluation
A. Prasanth Saraswati et al.
ACS MEDICINAL CHEMISTRY LETTERS (2020)
Recent progress on HDAC inhibitors with dual targeting capabilities for cancer treatment
Xiaopeng Peng et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2020)
Hydroxamic acid hybrids as the potential anticancer agents: An Overview
Wenhua Liu et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2020)
Therapeutic potential of CKD-506, a novel selective histone deacetylase 6 inhibitor, in a murine model of rheumatoid arthritis
Jin Kyun Park et al.
ARTHRITIS RESEARCH & THERAPY (2020)
HDAC6 inhibitor Cay10603 inhibits high glucose-induced oxidative stress, inflammation and apoptosis in retinal pigment epithelial cells via regulating NF-κB and NLRP3 inflammasome pathway
Qingsong Yang et al.
GENERAL PHYSIOLOGY AND BIOPHYSICS (2020)
An Update on JAK Inhibitors
Francesca Musumeci et al.
CURRENT MEDICINAL CHEMISTRY (2019)
The selective HDAC6 inhibitor Nexturastat A induces apoptosis, overcomes drug resistance and inhibits tumor growth in multiple myeloma
Xiaoyang Sun et al.
BIOSCIENCE REPORTS (2019)
Tubastatin A, an inhibitor of HDAC6, enhances temozolomide-induced apoptosis and reverses the malignant phenotype of glioblastoma cells
Alejandro Urdiciain et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2019)
HDAC6 selective inhibition of melanoma patient T-cells augments anti-tumor characteristics
Andressa S. Laino et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
High-selective HDAC6 inhibitor promotes HDAC6 degradation following autophagy modulation and enhanced antitumor immunity in glioblastoma
Jia-Rong Liu et al.
BIOCHEMICAL PHARMACOLOGY (2019)
Selective Inhibition of Histone Deacetylase 10: Hydrogen Bonding to the Gatekeeper Residue is Implicated
Magalie Geraldy et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Histone deacetylases in cardiovascular and metabolic diseases
Rushita A. Bagchi et al.
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY (2019)
HDAC6 inhibition blocks inflammatory signaling and caspase-1 activation in LPS-induced acute lung injury
Li Liu et al.
TOXICOLOGY AND APPLIED PHARMACOLOGY (2019)
Anti-metastatic activity of MPTOG211, a novel HDAC6 inhibitor, in human breast cancer cells in vitro and in vivo
Yi-Ling Hsieh et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2019)
Design, Synthesis, and Biological Evaluation of 2,4-Imidazolinedione Derivatives as HDAC6 Isoform-Selective Inhibitors
Tao Liang et al.
ACS MEDICINAL CHEMISTRY LETTERS (2019)
Selective HDAC6 inhibitors improve anti-PD-1 immune checkpoint blockade therapy by decreasing the anti-inflammatory phenotype of macrophages and down-regulation of immunosuppressive proteins in tumor cells
Tessa Knox et al.
SCIENTIFIC REPORTS (2019)
Quantitative Proteomic Analysis Reveals the Sites Related to Acetylation and Mechanism of ACY-1215 in Acute Liver Failure Mice
Wen-bin Zhang et al.
FRONTIERS IN PHARMACOLOGY (2019)
HDAC-selective Inhibitor Cay10603 Has Single Anti-tumour Effect in Burkitt's Lymphoma Cells by Impeding the Cell Cycle
Xiu-juan Ma et al.
CURRENT MEDICAL SCIENCE (2019)
Multitarget Approach for the Treatment of Alzheimer's Disease: Inhibition of Phosphodiesterase 9 (PDE9) and Histone Deacetylases (HDACs) Covering Diverse Selectivity Profiles
Obdulia Rabal et al.
ACS CHEMICAL NEUROSCIENCE (2019)
Structure-activity relationship study of thiazolyl-hydroxamate derivatives as selective histone deacetylase 6 inhibitors
Gibeom Nam et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2019)
Discovery of a New Isoxazole-3-hydroxamate-Based Histone Deacetylase 6 Inhibitor SS-208 with Antitumor Activity in Syngeneic Melanoma Mouse Models
Sida Shen et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Protective Effects of ACY-1215 Against Chemotherapy-Related Cognitive Impairment and Brain Damage in Mice
Dongmei Wang et al.
NEUROCHEMICAL RESEARCH (2019)
Histone deacetylase 6 inhibitor tubastatin A attenuates angiotensin II-induced hypertension by preventing cystathionine γ-lyase protein degradation
Zhexi Chi et al.
PHARMACOLOGICAL RESEARCH (2019)
Selective Inhibition of Histone Deacetylases 1/2/6 in Combination with Gemcitabine: A Promising Combination for Pancreatic Cancer Therapy
Richard S. Laschanzky et al.
CANCERS (2019)
Structural Basis of Catalysis and Inhibition of HDAC6 CD1, the Enigmatic Catalytic Domain of Histone Deacetylase 6
Jeremy D. Osko et al.
BIOCHEMISTRY (2019)
Ricolinostat (ACY-1215) inhibits VEGF expression via PI3K/AKT pathway and promotes apoptosis in osteoarthritic osteoblasts
Lei Li et al.
BIOMEDICINE & PHARMACOTHERAPY (2019)
Brain Penetrable Histone Deacetylase 6 Inhibitor SW-100 Ameliorates Memory and Learning Impairments in a Mouse Model of Fragile X Syndrome
Alan P. Kozikowski et al.
ACS CHEMICAL NEUROSCIENCE (2019)
ACY-1215 exhibits anti-inflammatory and chondroprotective effects in human osteoarthritis chondrocytes via inhibition of STAT3 and NF-κB signaling pathways
Chao Cheng et al.
BIOMEDICINE & PHARMACOTHERAPY (2019)
Design, synthesis, and bioactivity evaluation of novel Bcl-2/HDAC dual-target inhibitors for the treatment of multiple myeloma
Ruolan Zhou et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2019)
Structural and energetic basis for the inhibitory selectivity of both catalytic domains of dimeric HDAC6
Yudibeth Sixto-Lopez et al.
JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS (2019)
Quinazolin-2,4-dione-Based Hydroxamic Acids as Selective Histone Deacetylase-6 Inhibitors for Treatment of Non-Small Cell Lung Cancer
Chao-Wu Yu et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Synthesis and Biological Investigation of Phenothiazine-Based Benzhydroxamic Acids as Selective Histone Deacetylase 6 Inhibitors
Katharina Voegerl et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Development of Thiazolidinedione-Based HDAC6 Inhibitors to Overcome Methamphetamine Addiction
Chiranjeev Sharma et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Developing potent PROTACs tools for selective degradation of HDAC6 protein
Zixuan An et al.
PROTEIN & CELL (2019)
Inhibition of HDAC6 alleviating lipopolysaccharide-induced p38MAPK phosphorylation and neuroinflammation in mice
Yuanjian Song et al.
PHARMACEUTICAL BIOLOGY (2019)
Results of an abbreviated Phase Ib study of the HDAC6 inhibitor ricolinostat and paclitaxel in recurrent ovarian, fallopian tube, or primary peritoneal cancer
Elizabeth K. Lee et al.
GYNECOLOGIC ONCOLOGY REPORTS (2019)
Combination of a novel HDAC6 inhibitor ACY-241 and anti-PD-L1 antibody enhances anti-tumor immunity and cytotoxicity in multiple myeloma
A. Ray et al.
LEUKEMIA (2018)
Combination of a Histone Deacetylase 6 Inhibitor and a Somatostatin Receptor Agonist Synergistically Reduces Hepatorenal Cystogenesis in an Animal Model of Polycystic Liver Disease
Maria Lorenzo Pisarello et al.
AMERICAN JOURNAL OF PATHOLOGY (2018)
The recent progress of isoxazole in medicinal chemistry
Jie Zhu et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2018)
Synthesis and biological evaluation of novel benzofuroxan-based pyrrolidine hydroxamates as matrix metalloproteinase inhibitors with nitric oxide releasing activity
Hao Zhang et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2018)
Synthesis and biological evaluation of histone deacetylase and DNA topoisomerase II-Targeted inhibitors
Mitsuaki Yamashita et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2018)
Merging of ruxolitinib and vorinostat leads to highly potent inhibitors of JAK2 and histone deacetylase 6 (HDAC6)
Lianbin Yao et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2018)
Development of the first small molecule histone deacetylase 6 (HDAC6) degraders
Ka Yang et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2018)
NK Cells Mediate Synergistic Antitumor Effects of Combined Inhibition of HDAC6 and BET in a SCLC Preclinical Model
Yan Liu et al.
CANCER RESEARCH (2018)
Blockade of histone deacetylase 6 protects against cisplatin-induced acute kidney injury
Jinhua Tang et al.
CLINICAL SCIENCE (2018)
1-Aroylindoline-hydroxamic acids as anticancer agents, inhibitors of HSP90 and HDAC
Ritu Ojha et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2018)
Design and biological evaluation of tetrahydro-beta-carboline derivatives as highly potent histone deacetylase 6 (HDAC6) inhibitors
Michel Leonhardt et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2018)
Design, synthesis, biological evaluation and in vivo testing of dual phosphodiesterase 5 (PDE5) and histone deacetylase 6 (HDAC6)-selective inhibitors for the treatment of Alzheimer's disease
Obdulia Rabal et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2018)
Recent advances in the discovery of potent and selective HDAC6 inhibitors
Xiu-Xiu Wang et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2018)
A novel HDAC6 inhibitor exerts an anti-cancer effect by triggering cell cycle arrest and apoptosis in gastric cancer
Jing Dong et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2018)
The HDAC6 inhibitor ACY-1215 enhances the anticancer activity of oxaliplatin in colorectal cancer cells
Dong Hoon Lee et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2018)
被撤回的出版物: Silence of HDAC6 suppressed esophageal squamous cell carcinoma proliferation and migration by disrupting chaperone function of HSP90 (Retracted article. See vol. 122, pg. 1975, 2021)
Hua Tao et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2018)
(N-Hydroxycarbonylbenylamino)quinolines as Selective Histone Deacetylase 6 Inhibitors Suppress Growth of Multiple Myeloma in Vitro and in Vivo
Hsueh-Yun Lee et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Marbostat-100 Defines a New Class of Potent and Selective Antiinflammatory and Antirheumatic Histone Deacetylase 6 Inhibitors
Andreas Sellmer et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Discovery of Janus Kinase 2 (JAK2) and Histone Deacetylase (HDAC) Dual Inhibitors as a Novel Strategy for the Combinational Treatment of Leukemia and Invasive Fungal Infections
Yahui Huang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
The Unfolded Protein Response: A Novel Therapeutic Target for Poor Prognostic BRAF Mutant Colorectal Cancer
Nicholas Forsythe et al.
MOLECULAR CANCER THERAPEUTICS (2018)
A452, an HDAC6-selective inhibitor, synergistically enhances the anticancer activity of chemotherapeutic agents in colorectal cancer cells
Hye-Rim Won et al.
MOLECULAR CARCINOGENESIS (2018)
Multicomponent Synthesis and Binding Mode of Imidazo[1,2-a]pyridine-Capped Selective HDAC6 Inhibitors
Marcel K. W. Mackwitz et al.
ORGANIC LETTERS (2018)
The novel histone de acetylase 6 inhibitor, MPT0G211, ameliorates tau phosphorylation and cognitive deficits in an Alzheimer's disease model
Sheng-Jun Fan et al.
CELL DEATH & DISEASE (2018)
Novel spiroindoline HDAC inhibitors: Synthesis, molecular modelling and biological studies
Margherita Brindisi et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2018)
Design and synthesis of potent dual inhibitors of JAK2 and HDAC based on fusing the pharmacophores of XL019 and vorinostat
Yu-yi Chu-Farseeva et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2018)
Evaluation of WO2017018805: 1,3,4-oxadiazole sulfamide derivatives as selective HDAC6 inhibitors
Yuan-Yuan Liang et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2018)
Therapeutic potential of oxazole scaffold: a patent review (2006-2017)
Ramandeep Kaur et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2018)
Protective Effect of Tubastatin A in CLP-Induced Lethal Sepsis
Qiufang Deng et al.
INFLAMMATION (2018)
Histone deacetylase 6 in cancer
Ting Li et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)
A highly HDAC6-selective inhibitor acts as a fluorescent probe
Yi-Hsun Ho et al.
ORGANIC & BIOMOLECULAR CHEMISTRY (2018)
Hybrid topoisomerase I and HDAC inhibitors as dual action anticancer agents
Raffaella Cincinelli et al.
PLOS ONE (2018)
Ricolinostat (ACY-1215) suppresses proliferation and promotes apoptosis in esophageal squamous cell carcinoma via miR-30d/PI3K/AKT/mTOR and ERK pathways
Jinlin Cao et al.
CELL DEATH & DISEASE (2018)
Design, synthesis, and biological evaluation of histone deacetylase inhibitors possessing glutathione peroxidase-like and antioxidant activities against Alzheimer's disease
Jinhui Hu et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2018)
Structure, Functions and Selective Inhibitors of HDAC6
Tao Liang et al.
CURRENT TOPICS IN MEDICINAL CHEMISTRY (2018)
Discovery of the First-in-Class Dual Histone Deacetylase-Proteasome Inhibitor
Sanil Bhatia et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
HDAC6 inhibition protects cardiomyocytes against doxorubicin-induced acute damage by improving alpha-tubulin acetylation
Rui Song et al.
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY (2018)
Molecular Basis for the Selective Inhibition of Histone Deacetylase 6 by a Mercaptoacetamide Inhibitor
Nicholas J. Porter et al.
ACS MEDICINAL CHEMISTRY LETTERS (2018)
A potent hydroxamic acid-based, small-molecule inhibitor A452 preferentially inhibits HDAC6 activity and induces cytotoxicity toward cancer cells irrespective of p53 status
Hyun-Wook Ryu et al.
CARCINOGENESIS (2018)
Searching the conformational complexity and binding properties of HDAC6 through docking and molecular dynamic simulations
Yudibeth Sixto-Lopez et al.
JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS (2017)
Induced protein degradation: an emerging drug discovery paradigm
Ashton C. Lai et al.
NATURE REVIEWS DRUG DISCOVERY (2017)
Development of Improved HDAC6 Inhibitors as Pharmacological Therapy for Axonal Charcot-Marie-Tooth Disease
Veronick Benoy et al.
NEUROTHERAPEUTICS (2017)
Selective HDAC inhibition by ACY-241 enhances the activity of paclitaxel in solid tumor models
Pengyu Huang et al.
ONCOTARGET (2017)
Tubacin, an HDAC6 Selective Inhibitor, Reduces the Replication of the Japanese Encephalitis Virus via the Decrease of Viral RNA Synthesis
Chien-Yi Lu et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)
Targeted protein degradation by PROTACs
Taavi K. Neklesa et al.
PHARMACOLOGY & THERAPEUTICS (2017)
Unusual zinc-binding mode of HDAC6-selective hydroxamate inhibitors
Nicholas J. Porter et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
Synthesis and Pharmacological Evaluation of Selective Histone Deacetylase 6 Inhibitors in Melanoma Models
Mauricio T. Tavares et al.
ACS MEDICINAL CHEMISTRY LETTERS (2017)
Design and Synthesis of Mercaptoacetamides as Potent, Selective, and Brain Permeable Histone Deacetylase 6 Inhibitors
Wei Lv et al.
ACS MEDICINAL CHEMISTRY LETTERS (2017)
Synergistic Immunostimulatory Effects and Therapeutic Benefit of Combined Histone Deacetylase and Bromodomain Inhibition in Non-Small Cell Lung Cancer
Dennis O. Adeegbe et al.
CANCER DISCOVERY (2017)
Developing selective histone deacetylases (HDACACs) inhibitors through ebselen and analogs
Yuren Wang et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2017)
HDAC6 inhibitor WT161 downregulates growth factor receptors in breast cancer
Teru Hideshima et al.
ONCOTARGET (2017)
Enhancement of pomalidomide anti-tumor response with ACY-241, a selective HDAC6 inhibitor
Brian J. North et al.
PLOS ONE (2017)
Structure-Activity Relationship of Propargylamine-Based HDAC Inhibitors
Matthias Wuensch et al.
CHEMMEDCHEM (2017)
Multi-Targeted Anticancer Agents
Wei Zheng et al.
CURRENT TOPICS IN MEDICINAL CHEMISTRY (2017)
An inhibitor of histone deacetylase 6 activity, ACY-1215, reduces cAMP and cyst growth in polycystic kidney disease
Murali K. Yanda et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2017)
Design, synthesis, and evaluation of DNA topoisomerase II-targeted nucleosides
Hironobu Matsumoto et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2017)
Why Hydroxamates May Not Be the Best Histone Deacetylase InhibitorsWhat Some May Have Forgotten or Would Rather Forget?
Sida Shen et al.
CHEMMEDCHEM (2016)
Identification of HDAC6-Selective Inhibitors of Low Cancer Cell Cytotoxicity
Irina N. Gaisina et al.
CHEMMEDCHEM (2016)
Synthesis and Biological Investigation of Oxazole Hydroxamates as Highly Selective Histone Deacetylase 6 (HDAC6) Inhibitors
Johanna Senger et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
Computer-aided identification of new histone deacetylase 6 selective inhibitor with anti-sepsis activity
Jakyung Yoo et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2016)
Inside HDACs with more selective HDAC inhibitors
Joelle Roche et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2016)
Design and Synthesis of Janus Kinase 2 (JAK2) and Histone Deacetlyase (HDAC) Bispecific Inhibitors Based on Pacritinib and Evidence of Dual Pathway Inhibition in Hematological Cell Lines
Eugene Guorong Yang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial
Anas Younes et al.
LANCET ONCOLOGY (2016)
Histone deacetylase 6 structure and molecular basis of catalysis and inhibition
Yang Hai et al.
NATURE CHEMICAL BIOLOGY (2016)
Structural insights into HDAC6 tubulin deacetylation and its selective inhibition
Yasuyuki Miyake et al.
NATURE CHEMICAL BIOLOGY (2016)
HPOB, an HDAC6 inhibitor, attenuates corticosterone-induced injury in rat adrenal pheochromocytoma PC12 cells by inhibiting mitochondrial GR translocation and the intrinsic apoptosis pathway
Zong-yang Li et al.
NEUROCHEMISTRY INTERNATIONAL (2016)
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
Andrew W. Roberts et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
HDAC6 promotes cell proliferation and confers resistance to gefitinib in lung adenocarcinoma
Zhihao Wang et al.
ONCOLOGY REPORTS (2016)
Discovery of selective small-molecule HDAC6 inhibitor for overcoming proteasome inhibitor resistance in multiple myeloma
Teru Hideshima et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
Development of chidamide for peripheral T-cell lymphoma, the first orphan drug approved in China
Xianping Lu et al.
INTRACTABLE & RARE DISEASES RESEARCH (2016)
A Phase I Study of CUDC-101, a Multitarget Inhibitor of HDACs, EGFR, and HER2, in Combination with Chemoradiation in Patients with Head and Neck Squamous Cell Carcinoma
Thomas J. Galloway et al.
CLINICAL CANCER RESEARCH (2015)
Novel Bioactive Hybrid Compound Dual Targeting Estrogen Receptor and Histone Deacetylase for the Treatment of Breast Cancer
Chu Tang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
Targeting histone deacetylase 6 mediates a dual anti-melanoma effect: Enhanced antitumor immunity and impaired cell proliferation
K. V. Woan et al.
MOLECULAR ONCOLOGY (2015)
Development of a histone deacetylase 6 inhibitor and its biological effects
Ju-Hee Lee et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
Histone deacetylase 6 in health and disease
Carole Seidel et al.
EPIGENOMICS (2015)
Rational approaches, design strategies, structure activity relationship and mechanistic insights for anticancer hybrids
Kunal Nepali et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2014)
Acetylation of the KXGS motifs in tau is a critical determinant in modulation of tau aggregation and clearance
Casey Cook et al.
HUMAN MOLECULAR GENETICS (2014)
Phase II trial of panobinostat, an oral pan-deacetylase inhibitor in patients with primary myelofibrosis, post-essential thrombocythaemia, and post-polycythaemia vera myelofibrosis
Daniel J. DeAngelo et al.
BRITISH JOURNAL OF HAEMATOLOGY (2013)
Selective class IIa histone deacetylase inhibition via a nonchelating zinc-binding group
Mercedes Lobera et al.
NATURE CHEMICAL BIOLOGY (2013)
Development of a histone deacetylase 6 inhibitor and its biological effects
Ju-Hee Lee et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
SAR and in vivo evaluation of 4-aryl-2-aminoalkylpyrimidines as potent and selective Janus kinase 2 (JAK2) inhibitors
Timothy Forsyth et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2012)
Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma
Loredana Santo et al.
BLOOD (2012)
The Synergistic Effects of DNA-Targeted Chemotherapeutics and Histone Deacetylase Inhibitors As Therapeutic Strategies for Cancer Treatment
M. Stiborova et al.
CURRENT MEDICINAL CHEMISTRY (2012)
Protein Aggregates Are Recruited to Aggresome by Histone Deacetylase 6 via Unanchored Ubiquitin C Termini
Hui Ouyang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
Structural Basis for Sirtuin Activity and Inhibition
Hua Yuan et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
Selective Histone Deacetylase 6 Inhibitors Bearing Substituted Urea Linkers Inhibit Melanoma Cell Growth
Joel A. Bergman et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
Structure and property based design, synthesis and biological evaluation of γ-lactam based HDAC inhibitors
Eunhyun Choi et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2011)
The Role of HDAC6 in Cancer
Grace I. Aldana-Masangkay et al.
JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY (2011)
Discovery of the Macrocycle 11-(2-Pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (SB1518), a Potent Janus Kinase 2/Fms-Like Tyrosine Kinase-3 (JAK2/FLT3) Inhibitor for the Treatment of Myelofibrosis and Lymphoma
Anthony D. William et al.
JOURNAL OF MEDICINAL CHEMISTRY (2011)
Histone deacetylases as regulators of inflammation and immunity
Melanie R. Shakespear et al.
TRENDS IN IMMUNOLOGY (2011)
Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms
Alfonso Quintas-Cardama et al.
BLOOD (2010)
Rational Design and Simple Chemistry Yield a Superior, Neuroprotective HDAC6 Inhibitor, Tubastatin A
Kyle V. Butler et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2010)
Regulation of Cellular Metabolism by Protein Lysine Acetylation
Shimin Zhao et al.
SCIENCE (2010)
Dynamic DNA Methylation
Julie A. Law et al.
SCIENCE (2009)
Traversing the coordination chemistry and chemical biology of hydroxamic acids
Rachel Codd
COORDINATION CHEMISTRY REVIEWS (2008)
Use of the nitrile oxide cycloaddition (NOC) reaction for molecular probe generation: A new class of enzyme selective histone deacetylase inhibitors (HDACIs) showing picomolar activity at HDAC6
Alan P. Kozikowski et al.
JOURNAL OF MEDICINAL CHEMISTRY (2008)
Stepwise chromatin remodelling by a cascade of transcription initiation of non-coding RNAs
Kouji Hirota et al.
NATURE (2008)
HDAC6 is a specific deacetylase of peroxiredoxins and is involved in redox regulation
R. B. Parmigiani et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
HDAC6 modulates cell motility by altering the acetylation level of cortactin
Xiaohong Zhang et al.
MOLECULAR CELL (2007)
Epigenetics: A landscape takes shape
Aaron D. Goldberg et al.
CELL (2007)
Chromatin modifications and their function
Tony Kouzarides
CELL (2007)
Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma, (CTCL)
Madeleine Duvic et al.
BLOOD (2007)
Synthesis, enzymatic inhibition, and cancer cell growth inhibition of novel δ-lactam-based histone deacetylase (HDAC) inhibitors
Hwan Mook Kim et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2006)
Targeting histone deacetylase in cancer therapy
Hsiang-Yu Lin et al.
MEDICINAL RESEARCH REVIEWS (2006)
Synthesis and evaluation of estrogen receptor ligands with bridged oxabicyclic cores containing a diarylethylene motif: Estrogen antagonists of unusual structure
HB Zhou et al.
JOURNAL OF MEDICINAL CHEMISTRY (2005)
HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor
JJ Kovacs et al.
MOLECULAR CELL (2005)
Hydroxamic acids - An intriguing family of enzyme inhibitors and biomedical ligands
CJ Marmion et al.
EUROPEAN JOURNAL OF INORGANIC CHEMISTRY (2004)
Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor
A Vannini et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
The Janus kinases (Jaks)
K Yamaoka et al.
GENOME BIOLOGY (2004)
Antiestrogens and selective estrogen receptor modulators as multifunctional medicines. 1. Receptor interactions
VC Jordan
JOURNAL OF MEDICINAL CHEMISTRY (2003)
HDAC6 is a microtubule-associated deacetylase
C Hubbert et al.
NATURE (2002)
Histone deacetylase as a new target for cancer chemotherapy
M Yoshida et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2001)
Janus kinases: components of multiple signaling pathways
SG Rane et al.
ONCOGENE (2000)
Design and synthesis of piperazine-based matrix metalloproteinase inhibitors
MY Cheng et al.
JOURNAL OF MEDICINAL CHEMISTRY (2000)
Share Paper
